MRVI (Maravai LifeSciences Holdings) Total Liabilities: $344.1 Mil (As of Mar. 2026)


MRVI Maravai LifeSciences Holdings Inc MRVI
62 GF Score
Price $6.04
GF Value $3.82
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Maravai LifeSciences Holdings Total Liabilities?

Maravai LifeSciences Holdings MRVI -1.79% 62 Total Liabilities is $344.1 Mil as of Mar. 2026. GuruFocus rates MRVI with a GF Score™ of 62/100 and a GF Value™ of $3.82 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Maravai LifeSciences Holdings's Total Liabilities for the quarter that ended in Mar. 2026 was $344.1 Mil.

Maravai LifeSciences Holdings's quarterly Total Liabilities declined from Sep. 2025 ($417.33 Mil) to Dec. 2025 ($397.87 Mil) and declined from Dec. 2025 ($397.87 Mil) to Mar. 2026 ($344.13 Mil).

Maravai LifeSciences Holdings's annual Total Liabilities declined from Dec. 2023 ($697.57 Mil) to Dec. 2024 ($431.04 Mil) and declined from Dec. 2024 ($431.04 Mil) to Dec. 2025 ($397.87 Mil).

Maravai LifeSciences Holdings Total Liabilities Historical Data

* Premium members only.

The historical data trend for Maravai LifeSciences Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maravai LifeSciences Holdings Total Liabilities Chart

Maravai LifeSciences Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 1,372.92 1,377.07 697.57 431.04 397.87

Maravai LifeSciences Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 429.48 428.98 417.33 397.87 344.13
MRVI
62GF Score
Maravai LifeSciences Holdings Inc MRVI
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maravai LifeSciences Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Maravai LifeSciences Holdings's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=44.917+(350.507+0.19699999999995
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+2.245+0+0)
=397.9

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=770.577-372.711
=397.9

Maravai LifeSciences Holdings's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=42.622+(265.44+36.072
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=344.1

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=713.217-369.083
=344.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $344.1 Mil mean?
Maravai LifeSciences Holdings (MRVI) has a Total Liabilities of $344.1 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Maravai LifeSciences Holdings and its competitors.
Is Maravai LifeSciences Holdings' Total Liabilities too high?
Maravai LifeSciences Holdings' current Total Liabilities is $344.1 Mil. Overall, Maravai LifeSciences Holdings has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Maravai LifeSciences Holdings' Total Liabilities compare to LBRX and SLDB?
Maravai LifeSciences Holdings' Total Liabilities of $344.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Maravai LifeSciences Holdings and its competitors. Maravai LifeSciences Holdings's current Total Liabilities is $344.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maravai LifeSciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings (MRVI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.82, compared to a current price of $6.04 — trading 58.1% above its estimated fair value. The current Total Liabilities is $344.1 Mil. Maravai LifeSciences Holdings' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Maravai LifeSciences Holdings (MRVI), the current Total Liabilities is $344.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Maravai LifeSciences Holdings (MRVI) Overvalued in 2026?

Based on GuruFocus' analysis, Maravai LifeSciences Holdings stock appears to be overvalued. The current stock price of $6.04 is trading 58.1% above its estimated GF Value™ of $3.82. GuruFocus considers Maravai LifeSciences Holdings to be Significantly Overvalued.

Key valuation signals for MRVI:

  • Total Liabilities: $344.1 Mil
  • GF Value™: $3.82 vs. price of $6.04 (58.1% above fair value)
  • GF Score™: 62/100 with 8 warning signs

No single metric tells the full story. See the MRVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Maravai LifeSciences Holdings Business Description

Other Exchanges MAR:Germany
Address 10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
62GF Score

Get the complete analysis for MRVI

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.04
Price
$3.82
GF Value